Oculis (OCS) Competitors $19.54 -0.04 (-0.20%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$19.54 0.00 (-0.03%) As of 03/3/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends OCS vs. RYTM, VKTX, ACAD, CRNX, MRUS, MTSR, DNLI, XENE, MOR, and HCMShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Rhythm Pharmaceuticals (RYTM), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Crinetics Pharmaceuticals (CRNX), Merus (MRUS), Metsera (MTSR), Denali Therapeutics (DNLI), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Rhythm Pharmaceuticals Viking Therapeutics ACADIA Pharmaceuticals Crinetics Pharmaceuticals Merus Metsera Denali Therapeutics Xenon Pharmaceuticals MorphoSys HUTCHMED Oculis (NASDAQ:OCS) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Do analysts rate OCS or RYTM? Oculis presently has a consensus target price of $28.80, suggesting a potential upside of 47.39%. Rhythm Pharmaceuticals has a consensus target price of $68.27, suggesting a potential upside of 30.29%. Given Oculis' stronger consensus rating and higher probable upside, research analysts clearly believe Oculis is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Rhythm Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Which has more risk & volatility, OCS or RYTM? Oculis has a beta of -0.24, suggesting that its share price is 124% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Do insiders & institutionals have more ownership in OCS or RYTM? 22.3% of Oculis shares are held by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor OCS or RYTM? In the previous week, Rhythm Pharmaceuticals had 18 more articles in the media than Oculis. MarketBeat recorded 22 mentions for Rhythm Pharmaceuticals and 4 mentions for Oculis. Oculis' average media sentiment score of 0.94 beat Rhythm Pharmaceuticals' score of 0.24 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has stronger valuation and earnings, OCS or RYTM? Oculis has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$980K807.60-$98.92M-$1.93-10.12Rhythm Pharmaceuticals$130.13M24.75-$184.68M-$4.35-12.05 Is OCS or RYTM more profitable? Rhythm Pharmaceuticals has a net margin of -230.07% compared to Oculis' net margin of -8,043.28%. Oculis' return on equity of -71.31% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-8,043.28% -71.31% -56.85% Rhythm Pharmaceuticals -230.07%-367.36%-77.47% Does the MarketBeat Community believe in OCS or RYTM? Rhythm Pharmaceuticals received 272 more outperform votes than Oculis when rated by MarketBeat users. However, 90.32% of users gave Oculis an outperform vote while only 67.42% of users gave Rhythm Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOculisOutperform Votes2890.32% Underperform Votes39.68%Rhythm PharmaceuticalsOutperform Votes30067.42% Underperform Votes14532.58% SummaryOculis beats Rhythm Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$791.45M$7.22B$5.81B$8.39BDividend YieldN/A2.79%4.75%3.98%P/E Ratio-10.126.1524.9519.21Price / Sales807.60187.68375.54110.22Price / CashN/A65.6738.0534.58Price / Book6.816.447.334.28Net Income-$98.92M$139.03M$3.18B$247.04M7 Day Performance-6.42%-5.52%-4.42%-4.36%1 Month Performance-14.52%-8.56%-6.07%-5.59%1 Year Performance62.83%-14.59%11.42%3.39% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis2.2845 of 5 stars$19.54-0.2%$28.80+47.4%+62.8%$791.45M$980,000.00-10.122Short Interest ↑RYTMRhythm Pharmaceuticals4.0825 of 5 stars$54.66-2.5%$68.09+24.6%+19.9%$3.36B$112.53M-12.62140Earnings ReportAnalyst ForecastVKTXViking Therapeutics4.4556 of 5 stars$29.20-14.3%$97.29+233.2%-69.8%$3.25BN/A-29.2020ACADACADIA Pharmaceuticals4.5795 of 5 stars$19.48-2.4%$24.00+23.2%-24.4%$3.24B$929.24M24.97510Analyst RevisionNews CoverageCRNXCrinetics Pharmaceuticals4.2413 of 5 stars$34.62-7.6%$72.64+109.8%-25.8%$3.21B$4.01M-9.28210Earnings ReportMRUSMerus3.0178 of 5 stars$46.75-1.3%$85.92+83.8%-12.3%$3.20B$35.93M-11.8437Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionMTSRMetseraN/A$29.81-5.8%N/AN/A$3.07BN/A0.0081DNLIDenali Therapeutics4.3832 of 5 stars$20.67-0.3%$37.42+81.0%-27.1%$2.97B$330.53M-7.49430Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageXENEXenon Pharmaceuticals1.8226 of 5 stars$38.37-3.4%$57.38+49.5%-23.6%$2.93B$9.43M-13.61210Earnings ReportAnalyst RevisionNews CoverageMORMorphoSys0.12 of 5 stars$18.96flat$18.25-3.7%N/A$2.86B$238.28M-5.45730HCMHUTCHMED1.7074 of 5 stars$15.40-4.4%$19.00+23.4%+5.0%$2.68B$610.81M0.001,988Gap Down Related Companies and Tools Related Companies RYTM Competitors VKTX Competitors ACAD Competitors CRNX Competitors MRUS Competitors MTSR Competitors DNLI Competitors XENE Competitors MOR Competitors HCM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OCS) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
